Bamlanivimab and etesevimab combination has been authorised under Emergency Use Authorisation in the US and select EU countries for the treatment of the disease.
The drug baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization (CDSCO) for emergency use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19
To manufacture and commercialise baricitinib in India, approved for use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults